THIS DOCUMENT HAS THE PURPOSE OF

PRESENT WHO IS MERCK, WHAT IT DOES

AND ITS PROPOSALS FOR THE PRESENT

AND FUTURE HEALTH PROBLEMS SUCH AS

IVH, AIDS.

MERCK AS A COMPANY HAS HAD A BIG

DEVELOPMENT IN THE PHARMACEUTICAL

MARKET, THING THAT IT HAS RAISED BY ITS

INTEREST IN DISCOVER NEW MEDICINES

AS SOON A POSSIBLE TO CONTROL AND

CURE THE ILLNESS THAT ARE RUNNING

WITH THE PEOPLE´S LIFE.

ALEJANDRA CAROLINA OSSA JUAN SEBASTIAN BETANCUR M

VANESSA LEON URIBE

06/10/2011

2

TABLA DE CONTENIDO

MERCK ................................................................................................................................................................ 3

Our Vision ....................................................................................................................................................... 3

Our Mission .................................................................................................................................................... 3

What We Stand For ........................................................................................................................................ 3

OUR HISTORY ...................................................................................................................................................... 3

ABOUT US ........................................................................................................................................................... 3

OUR VALUES ....................................................................................................................................................... 5

RESPONSIBILITY ETHICS AND TRANSPARENCY ................................................................................................... 7

LEADERSHIP ........................................................................................................................................................ 7

HOW WE OPERATE ............................................................................................................................................. 8

CODE OF CONDUCT ............................................................................................................................................ 9

COMPLIANCE ...................................................................................................................................................... 9

OUR COMMITMENT TO PRIVACY ..................................................................................................................... 10

VIEWS AND POSITIONS ..................................................................................................................................... 11

ACCESS AND AFFORDABILITY ........................................................................................................................... 11

HEALTHCARE REFORM ..................................................................................................................................... 12

INNOVATION .................................................................................................................................................... 13

QUALITY & SAFETY ........................................................................................................................................... 13

SALES & MARKETING ........................................................................................................................................ 14

RESPONSIBLE PUBLIC POLICY AND ADVOCACY ................................................................................................ 14

ACCESS .............................................................................................................................................................. 15

ENVIRONMENT ................................................................................................................................................. 15

DISCOVERY AND DEVELOPMENT ...................................................................................................................... 16

COMMUNITY: FIGHTING HIV/AIDS ................................................................................................................... 16

Report from the United Nations about the AIDS in the 2010 ...................................................................... 17

Graphic No. 1: The number of people surviving with HIV continues to increase due to life-prolonging treatments ................................................................................................................................................... 18

Graphic No. 2: Treatment for HIV and AIDS is widespread, but not enough to meet the goal of universal access by 2010 ............................................................................................................................................. 19

Graphic No. 3: Work is progressing steadily in reducing HIV transmission to newborns ............................ 20

CONSUMER PRODUCTS .................................................................................................................................... 21

1. ISENTRESS® .......................................................................................................................................... 21

2. CRIXIVAN® ........................................................................................................................................... 22

CONCLUSION .................................................................................................................................................... 22

REFERENCES ..................................................................................................................................................... 23

3

MERCK

Our Vision

We make a difference in the lives of people globally through ourinnovative

medicines, vaccines, and consumer health and animal products. We aspire to be

the best healthcare company in the world and are dedicated to providing leading

innovations and solutions for tomorrow.

Our Mission

To provide innovative, distinctive products and services that save and improve

lives and satisfy customer needs, to be recognized as a great place to work, and to

provide investors with a superior rate of return.

What We Stand For

- Excellence in science and healthcare innovation, with an emphasis on

addressing unmet medical needs.

- Focus on patients and anticipating customers’ needs.

- Commitment to expand access to our medicines and vaccines, and to

improve global health.

OUR HISTORY

We've done great things in the past. Today, we're doing great things for the future.

Merck and Schering-Plough merged in November 2009 to create a new company.

Today, we are the second-largest healthcare company in the world. We also are a

global leader in consumer products and animal care.

Through the years, our researchers have helped to find new ways to treat and

prevent illness - from the discovery of vitamin B1, to the first measles vaccine, to

cold remedies and antacids, to the first statins to treat high cholesterol. Our

scientists also have helped develop many products to improve animal health,

including vaccines and antibiotics.

ABOUT US

4

TICKER MRK

NAME The company is known as Merck in the United States and Canada.

Everywhere else, we are known as MSD. Merck & Co., Inc. is the legal name and is listed on the New York Stock Exchange under the symbol "MRK."

DESCRIPTION

Merck is an innovative, global healthcare leader that is committed to improving health and well-being around the world.

Our product offering categories include heart and respiratory health, infectious diseases, sun care and women's health. We continue to focus our research on conditions that affect millions of people around the world - diseases like Alzheimer's, diabetes and cancer - while expanding our strengths in areas like vaccines and biologics.

We also devote extensive time and energy to increasing access to medicines and vaccines through far-reaching programs that donate and deliver our products to the people who need them.

At Merck, we're applying our global reach, financial strength and scientific excellence to do more of what we're passionate about: improving health and improving lives.

Merck. Be Well.

EMPLOYEES Approximately 93,000 employees worldwide (as of 3/31/11)

HEADQUARTERS Whitehouse Station, New Jersey

BUSINESSES Pharmaceuticals

Alliances Consumer Care Animal Health

2010 GAAP

Revenue

Merck $46.0 billion

2010 REVENUES MERCK

(By Geographic Region)

United States Europe, Middle East and Africa

Japan Other

$20.2 billion $13.5 billion $3.8 billion $8.5 billion

2010 R&D EXPENSE

Merck $11.0 billion

Merck is a global health care company that delivers innovative

5

PRODUCTS health solutions through its prescription medicines, vaccines, biologic therapies, and consumer and animal health products.

EXECUTIVE COMMITTEE

Kenneth C. Frazier, president and chief executive officer

Richard S. Bowles III, Ph.D., executive vice president and chief compliance officer

Peter S. Kim, Ph.D., executive vice president and president, Merck Research Laboratories

J. Chris Scalet, executive vice president, Global Services, and chief information officer

Adam H. Schechter, president, Global Human Health

Mervyn Turner, Ph.D., chief strategy officer and senior vice president, Emerging Markets R&D, Merck Research Laboratories

S o u r c e s : M e r c k b e w e l l

OUR VALUES

As an organization, our core values are driven by a desire to improve human life,

achieve scientific excellence, operate with the highest standards of integrity,

expand access to our products and employ a diverse workforce that values

collaboration.

- Improving human life

Our business is preserving and improving human life. We also work to

improve animal health.

All of our actions must be measured by our success in achieving these

goals.

- Ethics & integrity

We are committed to the highest standards of ethics and integrity.

We are responsible to our customers, to Merck employees, to the

environments we inhabit, and to the societies we serve worldwide.

6

In discharging our responsibilities, we do not take professional or ethical

shortcuts. Our interactions with all segments of society must be transparent

and reflect the high standards we profess.

- Innovation

We are dedicated to the highest level of scientific excellence.

Our research is guided by a commitment to preserving human and animal

health and the quality of life.

We strive to identify the most critical needs of consumers and customers,

and through continuous innovation we challenge ourselves to meet those

needs.

- Access for all

We aspire to improve the health and wellness of people around the world by

expanding access to our medicines and vaccines.

Creating new therapies is only the first step in battling disease and

promoting wellness on a global scale.

Success can only be achieved when everyone who needs our medicines

and vaccines can get them. In the United States and abroad, we've

developed numerous programs to help improve access to our products so

that all can benefit, wherever they live. One example of this situation is the

donation of a medicine called MECTIZAN®T through the program of

donation of MECTIZAN of MERCK to more than 30 countries around the

world, such as Brazil, Colombia, Guatemala, Ecuador, Venezuela and

Mexico.

- Diversity & teamwork

Our ability to excel depends on the integrity, knowledge, imagination, skill,

diversity and teamwork of our employees.

To this end, we work to create an environment of mutual respect,

encouragement and teamwork.

We reward commitment and performance and are responsive to the needs

of our employees and their families.

7

RESPONSIBILITY ETHICS AND TRANSPARENCY

Because millions of people around the world depend on our products, we have

high standards for how we should conduct ourselves as a company.

Our chief compliance officer, who reports directly to the CEO, is responsible for

ensuring high ethical standards and compliance across our business globally. This

includes: making sure that the company complies with all applicable laws and

regulations.

Our Office of Ethics supports our commitment to the highest standards of ethics

and integrity in all of our business practices. We map out clear expectations for

employees and hold them accountable for their behavior. We also have a number

of mechanisms available such as an Ombudsman office and global AdviceLine to

help counsel employees who face challenging situations.

We also remain committed to operating openly and with integrity. We have taken

significant steps recently to improve transparency, committing to public disclosure

of our financial support for third-party groups and for healthcare providers who

speak on behalf of Merck or our products. We also make sure that study results of

our marketed products-regardless of outcome-are made available quickly on

ClinicalTrials.gov.

LEADERSHIP

How we govern ourselves as a company is as important as anything else we do.

Good corporate governance benefits both our customers and our shareholders,

and is essential to our long-term business success.

For this reason, we devote considerable time and resources to making sure that:

our policies reflect our values and business goals;

we have an effective corporate governance structure; and

we are operating in a way that is open, honest and transparent.

8

HOW WE OPERATE

Our goal is to lead the way to a healthier future. But we also care about how we get

there together.

As a company whose products touch the lives and well being of people around the

world, we hold ourselves to a high standard. And we expect others to hold us to

that same high standard.

Diversity at Merck

We also value the diverse contributions of our employees around the world, and

are committed to creating a workplace that is open, welcome and respectful of all

of our employees.

“These values and principles are at the heart of who we are as a company.”

Diversity is the power of differences. We believe that having a diverse, inclusive

workforce and organization makes us a more innovative and agile company,

attuned to the needs of our customers.

Every day, we strive to create an inclusive workplace, where diverse

perspectives are respected and all opinions matter:

Diversity is woven throughout our business practices and training

strategy.

Our leaders are accountable for specific objectives related to diversity

and inclusion. Results are measured in terms of individual, division and

company-wide performance.

We provide equal employment opportunities to all qualified job

applicants.

We cast a wide net in our search for talent, seeking qualified suppliers –

large and small – from all segments of the business community. This

includes minority-, women- and veteran-owned businesses.

9

CODE OF CONDUCT

Our values and standards are the basis of our success. They always have been.

They always will be.

The people who use, recommend or prescribe our products have placed their trust

in us. No matter how strong our reputation, we must re - earn that trust every day

by practicing the values and standards that have guided this company for more

than 100 years.

Our code of conduct, which we publish for employees under the title Our Values

and Standards, helps to make sure that our employees understand what is

expected of them, and provides guidance on business standards and practices.

This is just one of the many ways that we continually reinforce the values on which

this company was built.

COMPLIANCE

Being an ethical company is about much more than simply adhering to the letter of

the law. But it’s an important step.

As part of our long-standing commitment to ethics and good corporate citizenship,

our first step is always to comply with the laws and regulations that govern the way

we market and sell our medicines, vaccines and other products.

We have a well-established compliance program that:

is consistent with recommendations set forth by the U.S. Department of

Health and Human Services and the Code on Interactions with

Healthcare Professionals created by the Pharmaceutical Research and

Manufacturers of America (PhRMA);

seeks to prevent, detect and resolve potential violations of law or

company policy; and

undergoes regular assessment and adjustment to make sure we are

being responsive to our evolving business and associated compliance

risks.

10

In addition, we:

require employees to report potential violations of law or company

policy;

hold ourselves accountable for responding promptly when potential

violations arise;

take disciplinary action as appropriate; and

examine whether identified violations are in part due to gaps in our

policies, practices or internal controls and, if so, take appropriate action

to prevent future violations.

Our compliance program is just one part of our overall commitment to operating

ethically, openly and transparently. But we believe it’s the right place to start.

OUR COMMITMENT TO PRIVACY

The new Merck privacy program is built on a strong foundation of global privacy

practices and standards and carries on our tradition of upholding high ethical

standards in collecting, using and disclosing personal information across our

business practices and in addressing privacy-related ethical issues in biomedical

research.

Privacy Trust at Merck:

We believe that trust is core to our privacy mission, so we have developed our

privacy program around the following key elements of privacy trust:

T - "transparency" - being open and clear about how we collect, use

and disclose personal information

R - "respecting choices" - such as whether or not people want to

participate in our programs

U - "understanding perspectives" - including that people have

different levels of concern about their privacy based on cultural

perspectives and personal experiences

S - "security" - protecting personal information from loss, misuse and

unauthorized access, disclosure, alteration or destruction

11

T - treating our stakeholders with respect and in a manner consistent

with the Company's values

VIEWS AND POSITIONS

We support public policies that advance the interests of patients, improve public

health and promote access to medicines and innovation.

We work to achieve our business objectives responsibly and respond to our many

stakeholders' needs and concerns. We support policies that promote the discovery

of innovative medicines and vaccines and make these products available to all who

need them.

To advance this objective, we:

develop policy positions that guide our activities and advocacy on a

range of issues;

seek opportunities to adopt industry-leading standards in several areas;

strive to communicate clearly and transparently about our positions;

and

work closely with the many groups and individuals who are also trying

to address the complex healthcare challenges that confront us.

ACCESS AND AFFORDABILITY

Through our business operations, public policy, and outreach efforts, we work to

adopt progressive positions and advocate for change that will improve access to

medicines and vaccines, while balancing our ability to continue to develop

innovative products to address healthcare needs.

The issues related to access are varied and complex. Our approach seeks to

combine our strengths and abilities, working in close partnership with governments,

donors, patient organizations, healthcare professionals, nongovernmental

organizations, multilateral organizations, and others in the private sector.

We are taking steps to advance this objective:

12

Through a multi-pronged strategy, we are improving access to medicines and

vaccines by examining our approach to research and development, manufacturing

and supply, registration, commercialization, and community investment.

In the developing world, including Africa and parts of Latin America and Asia, we

believe we have an important role and responsibility to help accelerate access to

our medicines and vaccines where access is most lacking. Access is determined

by many interrelated elements – some countries may lack basic medical

infrastructure, some patients may have limited access to hospitals or clinics, or in

some places there may be shortages of trained healthcare personnel. We have

taken this into account in our own work and how we work with others. We engage

in a wide range of public/private partnerships and other collaborations to spur

progress and new approaches to fighting diseases that affect the developing world,

such as AIDS.

In developed countries, access to medicines may be reduced by a lack of

affordable healthcare coverage or long waiting times before innovative medicines

are approved or made broadly available. We believe greater access can be

achieved through a strategy that combines the following:

pricing our products responsibly and, where necessary, donating our

products to those who lack healthcare coverage, such as through our

U.S. patient assistance programs;

advocating for healthcare reforms that will allow citizens greater access

to treatment and care through programs such as Medicare in the United

States. View our position on healthcare reform in the United States; and

promoting and participating in public/private partnerships to address

chronic and infectious disease and other complex health challenges.

HEALTHCARE REFORM

Merck believes all Americans should have access to quality, affordable health

insurance coverage. We are working to support healthcare reform in the U.S.

There are about 47 million people in the U.S. who do not have healthcare

coverage. And that number grows every year.

We believe the country must come together on this issue and we support

bipartisan healthcare reform that will ensure access to affordable healthcare

coverage for all Americans.

13

We are hopeful that our participation in the healthcare reform process and our

support for specific policies will help generate solutions that provide affordable

health insurance coverage for all.

INNOVATION

Innovation is the lifeblood of Merck. That is why we invested almost $5 billion in

research and development activities in 2008. Yet investment alone is not enough to

guarantee success.

Drug research is a high-risk and time-consuming process. Only 1 out of every

5000-10,000 compound screened becomes an approved drug. It takes an average

of 10 to 15 years at an average cost of more than US$1 billion to develop a

successful medicine.1

To deliver important products to the people who need them, we need a global

environment that supports the following enabling factors:

Intellectual Property Protection

Competition-based Healthcare

Government Support for Basic Biomedical Research

Evidence-based Regulatory Environment

Global Business Environment

QUALITY & SAFETY

From research and development to the manufacturing and distribution of our

medicines, vaccines and other products, safety and quality are our first

considerations.

We are committed to manufacturing quality products and demand equivalent

standards from our suppliers to help ensure patient safety.

Some of our quality and safety systems include:

Quality standards: We maintain policies, processes and procedures to help

ensure product quality.

14

Quality systems: Our global quality systems, made up of policies, processes

and procedures, are designed to ensure consistent product quality worldwide.

Education and training: We provide ongoing education and training

programs on quality and cGMP and on Good Clinical Practice (GCP) for our

employees.

Supplier standards: We maintain strict quality standards and insist on the

same from our suppliers and licensees, regardless of their location.

Adverse event reporting: We maintain an Adverse Event Reporting

database and global procedures to compile adverse event information and

ensure compliance regulations globally.

Safety monitoring: We have developed processes and procedures for the

timely and accurate monitoring of the safety profiles of our investigational and

marketed products.

SALES & MARKETING

We know that doctors and patients look to us to provide accurate and balanced

information about our products. We adhere to strict ethical sales and marketing

practices for all of our businesses, whether pharmaceuticals, vaccines, consumer

health or animal health.

We believe direct-to-consumer (DTC) advertising contributes to greater awareness

about conditions and diseases, which can benefit public health by increasing the

number of patients appropriately diagnosed and treated.

Our interactions with healthcare providers, other customers and consumers are

governed by laws and regulations, and by our global code of conduct which

includes standard business practices and compliance guidance. We take these

responsibilities seriously and periodically evaluate our marketing, sales and

advertising activities to ensure they align with the applicable laws, regulations and

Merck's policies and values.

RESPONSIBLE PUBLIC POLICY AND ADVOCACY

Merck is committed to participating constructively and responsibly in the political

process. Government proposals to regulate the health care system may directly

15

affect the company's business and incentives for pharmaceutical innovation. Also,

there are important policy initiatives that can further the company's goals with

respect to increasing patient access to medicines and vaccines -- particularly for

patients in disadvantaged communities and regions -- and, most importantly, to

health care insurance coverage. It is appropriate for the company to help inform

the debate on these issues in the United States and in other countries, and to do

so in a responsible and ethical way.

ACCESS

We discover and develop medicines and vaccines for millions of people around the

world. But that’s not enough if people can’t access them.

We know that not everyone who needs our medicines and vaccines can get them –

whether because of an inability to see a doctor for a diagnosis or to pay for a

needed treatment.

In the United States, we are working to support much-needed reform of the

country’s healthcare system so people have insurance coverage. In the meantime,

we continue to make available and enhance our Patient Assistance Program so the

uninsured can receive our medicines and vaccines for free.

In other parts of the world, we have created numerous programs and public/private

partnerships to help improve healthcare capacity and improve access to our

products so all can benefit, wherever they live.

ENVIRONMENT

We at Merck remain dedicated to being environmentally responsible in how we

manufacture our medicines and vaccines. And we work hard to reduce our

environmental impact through stewardship of natural resources like water, by

conserving energy and also by appropriately eliminating waste.

We also go beyond the direct impact of our business to positively influence the

environment. Our main way of doing so is through financial support of non-

governmental organizations and their local partners to protect ecological resources

around the world.

16

DISCOVERY AND DEVELOPMENT

The work we do in our labs has helped to save and improve countless lives.

Thanks to our world-class researchers, state-of-the-art technologies and

unrelenting focus on scientific excellence, Merck is at the forefront of discovering

and developing new ways to treat and prevent disease.

Scientific discovery and development have always been the cornerstones of our

company. Today, we conduct research in a broad range of therapeutic categories –

including cardiovascular disease, infectious diseases, vaccines, cancer, neurology

and women’s health. And, to help achieve our goal of saving and improving lives

around the world, we are expanding our capabilities in new areas, such as

biologics.

COMMUNITY: FIGHTING HIV/AIDS

Working in Partnership against HIV/AIDS

In 2000, in response to the massive threat HIV and AIDS posed in the sub-

Saharan nation of Botswana, Merck joined with the Government of Botswana and

the Bill & Melinda Gates Foundation to form the African Comprehensive HIV/AIDS

Partnerships. The Merck Company Foundation committed an initial $56.5 million to

the partnership to provide treatment, care and support for people living with HIV

and AIDS, as well as to help prevent its further spread. In addition, Merck agreed

to donate its antiretroviral medicines to Botswana's national antiretroviral treatment

program for the partnership's duration.

The partners selected Botswana because it had one of the highest adult

prevalence rates of HIV and AIDS in the world, a viable existing healthcare

infrastructure and strong political will and commitment to address the challenges of

HIV and AIDS.

In 2007, ACHAP expanded its support to target co-infection of HIV and

tuberculosis (TB). HIV infection has fueled an explosive increase in TB cases in

Botswana since the early 1990s.

Building on the successes created by its initial investment, in 2010 Merck

contributed an additional $30 million over the next five years. The new funding will

continue the program's original efforts in treatment and care but also will support

the second phase initiatives to meet the current treatment needs of the 137,000

17

Batswana (people from Botswana) living with HIV and new patients enrolled in the

second phase. The second phase initiatives include: the prevention of HIV.

Report from the United Nations about the AIDS in the 2010

Sources: elmundo.es

18

Graphic No. 1: The number of people surviving with HIV continues to

increase due to life-prolonging treatments

Sources: CINU

Between 2004 and 2009, the number of people receiving antiretroviral treatment

for HIV or AIDS was multiplied by 13. As a result, deaths from this disease during

this period decreased by 19%. In addition to fewer new infections, infected people

live longer.

In 2009 there were 33.3 million people living with HIV, 27% more than in 1999.

Sub-Saharan Africa remains the region most affected: it has 69% of new HIV

infections, 68% of all HIV-positive population and 72% of AIDS deaths. However,

the epidemic has spread to other regions.

19

Graphic No. 2: Treatment for HIV and AIDS is widespread, but not enough

to meet the goal of universal access by 2010

Sources: CINU

In late 2009, in countries with low and middle income had 5.25 million people

receiving antiretroviral therapy. This represents an increase of more than 1.2

million people compared to December 2008, which saw the largest annual increase

ever recorded.

Some countries, including Botswana, Cambodia, Croatia, Cuba, Guyana, Oman,

Romania and Rwanda, have already achieved universal access (defined as

coverage of at least 80% of the population in need) to antiretroviral treatment and /

or interventions prevent HIV transmission.

The World Health Organization (WHO) revised its guidelines in 2009 regarding the

treatment of HIV-positive adults and adolescents, including pregnant women. As a

20

result, the number of people needing antiretroviral therapy defined increased from

10.1 to 14.6 million in late 2009.

Graphic No. 3: Work is progressing steadily in reducing HIV transmission

to newborns

Sources: CINU

Without treatment of the mother, about one third of children of HIV positive women

will become infected with the virus during pregnancy, childbirth or breastfeeding.

This risk can be greatly reduced if the pregnant woman is treated with antiretroviral

therapy.

In 2009, the number of HIV positive pregnant women receiving antiretroviral

therapy treatment was 53%, which only reached 45% in 2008. About 91% of the

1.4 million pregnant women needing treatment live in sub-Saharan Africa.

21

CONSUMER PRODUCTS

Through our consumer health products, we strive to enhance the quality of life for

people and their families around the world.

Each day, millions count on one or more of our industry-leading brands that help

prevent or treat various common conditions.

There are the most important and effectly product that we have to control the

human immunodeficiency virus (AIDS), which are:

1. ISENTRESS®

ISENTRESS is a human immunodeficiency virus integrase strand transfer

inhibitor (HIV-1 INSTI); an anti-HIV (antiretroviral) medicine used for the

treatment of HIV.

This medicine works blocking an enzyme called HIV integrase which the virus

(HIV) needs in order to make more virus.

Isentress is used in the mayority of cases with other anti-HIV medicines to

reduce the amount of the Human Immunodeficiency Virus (HIV) in the blood

and increase the number of white blood cells.

INGREDIENTS

Active ingredient: Each film-coated tablet contains 400 mg of raltegravir.

Inactive ingredients: Microcrystalline cellulose, lactose monohydrate, calcium

phosphate dibasic anhydrous, hypromellose 2208, poloxamer 407 (contains

0.01% butylated hydroxytoluene as antioxidant), sodium stearyl fumarate,

magnesium stearate. In addition, the film coating contains the following inactive

ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, talc,

red iron oxide and black iron oxide.

22

2. CRIXIVAN®

CRIXIVAN is an oral capsule used for the treatment of HIV (Human

Immunodeficiency Virus). HIV is the virus that causes AIDS (acquired immune

deficiency syndrome). CRIXIVAN is a type of HIV drug called a protease (PRO-

tee-ase) inhibitor.

CRIXIVAN is a protease inhibitor that fights HIV. CRIXIVAN can help reduce

your chances of getting illnesses associated with HIV. CRIXIVAN can also help

lower the amount of HIV in your body (called “viral load”) and raise your CD4

(T) cell count. CRIXIVAN may not have these effects in all patients.

CRIXIVAN is usually prescribed with other anti-HIV drugs such as ZDV (also

called AZT), 3TC, ddI, ddC, or d4T. CRIXIVAN works differently from these

other anti-HIV drugs. Talk with your doctor about how you should take

CRIXIVAN.

CONCLUSION

From this document we can observer that MERCK is an important and recognized

company that has a good position in the global pharmaceutical market and has

been involved in the discovering of infinitive of medicines to improve the human

and animal health.

MERCK is one of the most interested in help to save the humans from illnesses

that are destroying them; one example of this is the donation o medicine to control

the AISD and the intervention on the healthcare reform in The United States to

improve the human welfare and reduce de mortality rate.

In summary and to end we can say that MERCK with its discovers and thought to

the future could be a excellent group with the government of each country

interested in improve the human welfare to try of raising all their projects together.

23

REFERENCES

- Source: Merck be well

http://www.merck.com/about/Merck%20Corporate%20Ads.pdf, retrieved on

September 24 of 2011.

- Source: CIRU “Centro de Información de las Naciones Unidas”

http://www.cinu.mx/minisitio/ODM2011/docs/InformeODM2011.pdf, retrieved on

October 03 of 2011.

- Sources: elmundo.es

http://www.elmundo.es/elmundosalud/documentos/2010/11/onusida/est_mundo

_2010.html, retrieved on October 05 of 2011.

- Sources: MSD

http://www.msd.com.co/msdco/corporate/index.html, retrieved on October 05 of

2011.

- Sources: The Merck group

http://www.merckgroup.com/en/index.html, retrieved on October 06 of 2011.

- Sources: Merck

http://www.merck-chemicals.com/, retrieved on October 06 of 2011.

- Sources: The Merck manual

http://www.merckmanuals.com/professional/index.html, retrieved on October 06

of 2011.

- Sources: The sacramento bee

http://www.sacbee.com/2011/10/05/3961844/hivaids-therapeutics-market-

to.html, retrieved on October 06 of 2011.